The cloud IT vendor said it now gives patients a no-login, digital identity-based access system to exercise greater control ...

VESPER-1 and interim VESPER-3 data release expected in September 2025; Phase 3 initiation on track for late 2025 MET-233i (once-monthly amylin analog) delivered class-leading Phase 1 results including ...

Multidrug-resistant bacteria kill five million people each year, with newly resistant germs emerging faster than scientists ...

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today ...

AbCellera's AI-driven drug discovery model hasn't translated into meaningful growth. Click here to read an analysis of ABCL ...

Some of the most interesting data are precisely those illustrating the reality of clinical practice of physicians attending ...

Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth -- ARCALYST 2025 expected net product revenue increased to $625 - $640 million -- KPL-387 ...

We will additionally search clinical ... flow diagram of the literature selection in this study. Actual screening numbers will be populated during the review process and reported in the final ...

We aimed to determine the association of rotaviral diarrhoea aetiology with prior vaccination, socioeconomic status and clinical factors in children ... (R Foundation for Statistical Computing). Flow ...

Mustang Bio Inc. company and executive profile by Barron's. View the latest MBIO company infomation and executive bios.

Studies suggest that some commercially available health tests are inaccurate and unsuitable for public use. Rebecca Coombes , Hristio Boytchev , and Gareth Iacobucci ask if regulation is adequately ...